Introduction {#S1}
============

Neuropilin-1 (Nrp1) is a 120--130 kDa type-I transmembrane glycoprotein with a multi-domain extracellular region, a single transmembrane helix, and a cytoplasmic domain. The extracellular region consists of two CUB domains (denoted a1/a2), two coagulation factor V/VIII homology domains (denoted b1/b2), and a MAM domain (denoted c) ([@B1]). Previous reports suggest that the a1/a2 and b1/b2 domains are involved in the binding of Nrp1 to its ligands ([@B2], [@B3]), whereas the c- and transmembrane domains participate in receptor dimerization ([@B4]). The intracellular domain interacts with PDZ domain proteins ([@B5]), yet its function is not defined (Figure [1](#F1){ref-type="fig"}).

![**Neuropilin-1 structure, ligands, and function**. Left: Nrp1 is comprised of five extracellular domains (a1/a2, b1/b2, and c), one transmembrane domain, and a short cytoplasmic domain. The a1/a2 and b1/b2 domains are involved in binding to several ligands, while the c- and transmembrane domains are involved in receptor oligomerization. The intracellular domain of Nrp1 interacts with PDZ domain proteins (such as synectin) via its C-terminal recognition sequence S-E-A. In addition, a natural-occurring soluble form of Nrp1 (sNrp1), lacking the c- and transmembrane domains, is shown. Right: the function and ligand binding properties of each Nrp1 domain is depicted.](fimmu-04-00405-g001){#F1}

Neuropilin-1 was first described to be involved in the development of neurons ([@B6]--[@B11]), where it plays an important role as co-receptor of various molecules, as described below ([@B12]--[@B19]). More recent, immunologists have been interested in Nrp1 due to its role in the formation of the immune synapse between dendritic cells (DCs) and T cells, leading to the activation of T cells ([@B20]--[@B23]).

In addition to its expression in different cell types, an important feature of Nrp1 is its ability to bind many different ligands; these ligands control a variety of biological processes through binding to Nrp1 ([@B13]--[@B19]). In this review, we discuss the identification of Nrp1 and its biology, and then focus on the relevance of Nrp1 in the immune system and its potential clinical use in transplant tolerance.

Neuropilin-1 biology {#S1-1}
--------------------

Initially known as A5, Nrp1 was identified in the late 80s as an antigen preferentially expressed on superficial layers of the optic tectum of *Xenopus laevis* through screening candidate molecules implicated in retinotectal projection development ([@B6]--[@B8]). The composition of these layers predominantly consist of synapses, glial processes, dendrites and axonal ends of retinal neurons, or "neuropiles," and therefore termed Neuropilin-1 ([@B8]).

During the 90s, research on Nrp1 was limited to the field of developmental biology. In mice, Nrp1 is expressed in olfactory, hippocampal, retinal, and sensory peripheral neurons; its expression varies according to the development stage and establishment of neuronal circuits ([@B9], [@B10]). Signaling through Nrp1 expressed on neurons promotes neurite outgrowth *in vitro*, which can be inhibited using anti-Nrp1 antibodies ([@B24]). In addition, systemic overexpression of Nrp1 under control of the β-actin promoter leads to embryonic death due to several morphological abnormalities, such as anomalous sprouting, defasciculation of nervous fibers, and cardiovascular abnormalities like excessive formation of capillaries, blood vessels, and heart malformation ([@B11]). Together, these observations suggest an important role for Nrp1 in embryonic vessel formation and neuronal interactions.

Several investigators subsequently reported that Nrp1 is a class III semaphorin (Sema3) receptor (discussed later), confirming an important role for Nrp1 in axonal guidance ([@B25]--[@B27]). These findings are consistent with Nrp1 being identified as a novel vascular and endothelial growth factor (VEGF) receptor ([@B12]), and a Nrp1 deficiency in mice resulting in embryonic lethality at 10--12.5 days due to severe anomalies in the vascular system, including impaired neural vascularization, absence and/or transposition of important vessels and disorganization of the extra embryonic vasculature ([@B28]). Taken together, these results demonstrated that Nrp1 is essential for normal embryological development of the nervous and cardiovascular systems.

Neuropilin-1 has a homologous protein called Neuropilin-2 (Nrp2), which shares 44% peptide sequence homology ([@B26], [@B29]). Both proteins have similar molecular weight, general domain structure, and share certain ligand specificities ([@B30], [@B31]). Furthermore, they can form Nrp1/Nrp2 heterodimers ([@B32], [@B33]). Nrp1 and Nrp2 are present only in vertebrates, despite the evidence indicating the existence of Nrp ligands in some invertebrates ([@B30], [@B34]). In addition to membrane-bound Nrp1 and Nrp2, several secreted forms of these proteins, which lack the transmembrane and cytoplasmic domains, have been identified and sought to act as natural inhibitors ([@B35]--[@B39]).

A notable feature of Nrp1 and Nrp2 is their ability to bind with relatively high affinity to several families of molecules, which involves them in a variety of physiological processes in a manner that is not yet fully understood. These molecules include Sema3 and heparin-binding members of the VEGF family that bind to Nrp1. VEGF family members are potent angiogenic molecules with chemotactic, survival, and proliferating effects in endothelial cells ([@B40]). Nrp1 is a functional receptor for specific members of the family of these angiogenic factors acting as a co-receptor together with VEGF-receptors ([@B12]). In addition, Nrp1 binds to hepatocyte growth factor (HGF and its receptor c-Met) ([@B13], [@B14]), some members of the fibroblast growing factor (FGF) family ([@B13]), platelet derived growth factor (PDGF and its receptors) ([@B15], [@B16]), and Galectin-1 (Gal-1) ([@B17]). Finally, Nrp1 interacts with integrins ([@B18], [@B19]) and even binds with itself ([@B13]), implicating a role in immune cells (discussed later).

Neuropilin-1 is expressed in epithelial cells from different tissues (e.g., gastrointestinal tract, pancreas, thymus), neurons, melanocytes, and keratinocytes ([@B31], [@B41]). In many cases, Nrp1 participates in the generation of various types of organs, which can be attributed largely to its role as a VEGF receptor. For example, Nrp1 is involved in pancreatic islet neogenesis and its expression is restricted to islet cells ([@B42]). Moreover, Nrp1 expression levels increase during lung organogenesis and its expression remains in normal alveolar epithelium ([@B43]). Nrp1 also participates in glomerulogenesis and wound repair in renal glomerular and keratinocytes, respectively ([@B44], [@B45]).

Neuropilin-1 is expressed by a variety of human tumor cell types ([@B46]), such as breast cancer cells, melanoma, astrocytoma, and prostate carcinoma, among others ([@B12], [@B47]--[@B49]). Although in certain clinical studies it was found a correlation between Nrp1 expression and increased hypervascularity, malignancy, and/or aggressiveness ([@B46]), sNRP1 (a soluble form of Nrp1) had a antitumoral effect ([@B35]).

Semaphorins and their relationship with Nrp1 in immune cells {#S1-2}
------------------------------------------------------------

Semaphorins are a family of either membrane-associated or soluble proteins that share a common structural domain known as a *Sema* domain ([@B50]). This family is composed of ∼30 different proteins that are involved in axonal guidance, as chemorepellents of neurite growth during central nervous system (CNS) development, proliferation, and cytoskeleton organization ([@B51]), organogenesis, vascularization, angiogenesis, and cancer ([@B50]). Furthermore, some semaphorins are present in different immune cells (Figure [2](#F2){ref-type="fig"}), including lymphocytes, Natural Killer (NK) cells, monocytes, DCs ([@B51]). These semaphorins belong to class III, IV, VI, and VII, and their roles in immune regulation are discussed below.

![**Neuropilin and semaphorin expression in immune cells**. Multiple immune cells express neuropilins and semaphorins and signaling through these molecules control distinct cellular properties including cell migration, activation, or modulation of immune cell response and CD4+ T-cell polarization. Some neuropilins and semaphorins are uniquely expressed in specific CD4+ T-cell subsets such as activated cells (red lined cells) or FoxP3+ regulatory T cells (gray cell).](fimmu-04-00405-g002){#F2}

### Class VII semaphorins {#S1-2-1}

Sema7A is a membrane-attached glycoprotein (also known as CD108), which is expressed on activated lymphocytes and thymocytes. Its receptor is VESPR/CD232/plexin-C1, present in monocytes and macrophages ([@B52]). Sema7A signaling induces the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-8, and the chemotaxis of monocytes ([@B53]). Studies using genetically manipulated mice suggested an important role for Sema7A in some immune diseases. For example, *Sema7a*-knockout mice are resistant to inflammation and it has been described that Sema7A is an important molecule in the pathogenesis of lung fibrosis, exacerbating fibrosis via binding to β1-integrin ([@B54]). Furthermore, signals through Sema7A on monocytes promotes the production of granulocyte-macrophage colony stimulating factor (GM-CSF), inducing morphological changes transforming them to a DCs-like morphology ([@B55]).

### Class VI semaphorins {#S1-2-2}

Sema6D is expressed on T cells, B cells, and NK cells. Its receptor is plexin-A1, known for being expressed specifically on DCs. Studies have demonstrated that recombinant Sema6D recognizes and binds to plexin-A1 on activated DCs, increasing IL-12 production. Additionally, Plexin-A1-knockout mice exhibit impaired T-cell responses, being resistant to experimental autoimmune encephalomyelitis (EAE). Specifically, it has been shown that Sema6D expression increases belatedly during CD4+ T-cell activation, and its blockade causes an impaired late-phase T-cell proliferation and the inhibition of CD127 expression ([@B56]). Also, it has been found that Sema6D is present in gastric carcinoma tissue where it would be playing an important role inducing angiogenesis ([@B57]).

### Class IV semaphorins {#S1-2-3}

Sema4D, also known as CD100, was the first semaphorin to be associated with an immune function ([@B58]). This molecule is expressed constitutively in T cells and at low levels in resting B cells and DCs, but is upregulated in these cells upon activation ([@B59], [@B60]). During this event Sema4D is proteolytically cleaved and is released as a soluble protein ([@B55]), which has been implicated in physiological and pathological immune responses ([@B54]). Soluble Sema4D has been detected in immunized mice ([@B50]). *Sema4d*-knockout mice have impaired humoral responses against T-cell-dependent antigens ([@B59]), and fail to develop EAE caused by an impaired priming of T cells by DCs, which is essential in the induction of antigen-specific T-cell responses ([@B60]).

Two receptors have been described for Sema4D: CD72 for lymphoid cells and Plexin-B1 for non-lymphoid cells ([@B55]). The cytoplasmic domain of CD72 has an immunoreceptor tyrosine-based inhibition motif (ITIM) that binds to SH2-containing tyrosine phosphatase 1 (SHP1) and acts as a negative regulator of B cell responses ([@B61], [@B62]). When Sema4D interacts with CD72, induces tyrosine dephosphorylation of the ITIM motif, turning off the negative signal by disrupting CD72-SHP1 interaction, and promoting positive stimulation of B cells ([@B59], [@B63]). It has been suggested that Sema4D could be the ligand for plexin-B1, reversing its roles and implying different functions for this semaphorin ([@B50]).

Sema4A is expressed in DCs, B cells, and activated T cells ([@B64]), especially in Th1-polarized cells ([@B65]), suggesting that Sema4A helps drive Th1 polarization. Sema4A is also expressed in Th17 cells ([@B66]). In the EAE model, mice treated with an anti-Sema4A blocking antibody were protected against the disease, as demonstrated by decreased numbers of infiltrating mononuclear cells into the CNS and diminished reactivity of myelin oligodendrocyte glycoprotein (MOG)-specific T cells ([@B64]). Analysis of *Sema4a*-deficient mice demonstrated that these animals have an impaired Th1-type response, and DCs from these mice were poor stimulators of allogeneic T cells, indicating a non-redundant role of Sem4A in DCs and T cells ([@B65]). The receptor of Sema4A in immune cells is Tim-2 ([@B64]), which is expressed by Th2-polarized cells, and its been suggested that the expression of Sema4A by Th1-polarized cells negatively regulates Th2 cell response via interaction with Tim-2 ([@B54]). Recently, it has been shown that Sema4A expressed in plasmacytoid dendritic cells (pDCs) can modulate anti-tumor responses by potentiating regulatory T-cell function and stability in the tumor microenvironment ([@B67]).

Sema4B is expressed in T cells and B cells, and promotes Th2 cell skewing ([@B68]). Supporting this observation, Sema4b^−/−^ mice have increased levels of serum IgE and an enhanced basophil-mediated IgE production. Although the receptor for Sema4B remains unidentified, it has been suggested that the regulatory properties of Sema4B in basophils would be mediated through ITIM-containing molecules ([@B54]).

### Class III semaphorins {#S1-2-4}

Sema3E is involved in thymocyte development ([@B69]). It is expressed on medullar thymic epithelial cells (mTECs), and CD4+CD8+ double positive (DP) thymocytes express high levels of Plexin-D1, the receptor for Sema3E. *Plxnd1*- and *Sema3e-*knockout mice have abnormal thymic development, with no clear cortical-medullary demarcation ([@B69]). In these mutant mice, CD69+ DP thymocytes localize in the cortical area in contrast to wild type mice where CD69+ DP thymocytes localize in the medullary zone of the thymus ([@B69]).

### Semaphorin 3A {#S1-2-5}

Sema3A acts as a negative regulator of the immune system ([@B54]), and is expressed in activated DCs and T cells, attenuating T-cell proliferation directly ([@B70]). Sema3A is also expressed in several tumor cells, inhibiting T-cell proliferation by activation of Ras/MAPK signaling pathway ([@B71]). The receptor of Sema3A is a complex formed by Nrp1 and plexin-A ([@B72]), and mutants for the receptors of Sema3A exhibit an enhanced T-cell response, both *in vitro* and *in vivo* ([@B73]). Furthermore, the *in vivo* administration of plasmid DNA encoding Sema3A reduces the severity of mice suffering from collagen-induced arthritis (CIA) ([@B74]). Given these findings, Sema3A is a potential target for the treatment of autoimmune diseases ([@B75], [@B76]).

Sema3A is also involved in thymocyte development and controlling the migration of immune cells ([@B77]). Acting as a chemorepellent, signaling through Sema3A impairs the migration of T cells and monocytes *in vitro* ([@B78], [@B79]). *In vivo*, Plexin-A1 deficient and Nrp1 defective mice have impaired T-cell responses due to the incapacity of DCs, that normally express both molecules, to transmigrate across lymphatic endothelial cells and to reach draining lymph nodes, where DCs encounter T cells to present the antigen ([@B80]). In the same work it is showed that DCs suffer morphological changes (cytoskeleton reorganization) during transmigration, which are Sema3A-dependent. These interactions would regulate DCs contractility and adhesion capabilities when passing through vessel walls ([@B54]).

In contrast to the immunosuppressive role of Sema3A, Wen et al. reported that macrophages and DCs from plexin-A4 knock out mice have defective cytokine production upon stimulation with TLR agonists. In the same work, administration of exogenous Sema3A exacerbates cytokine production in wild type cells, indicating that Sema3A is an enhancer of the innate immune response ([@B81]). Additional studies are needed to clarify the function of Sema3A in immune responses.

Nrp1 in T-cell-mediated immunity {#S1-3}
--------------------------------

### DCs and CD4+ T cells {#S1-3-6}

In 2002, Tordjman et al. described for the first time that Nrp1 is expressed on human DCs. Analysis of Nrp1 expression during *in vitro* differentiation from monocyte to DCs demonstrated that Nrp1 is not expressed in monocytes but only after differentiation into DCs ([@B20]). Nrp1 expression correlated with DC-SIGN. Consistent with these findings, Nrp1 is expressed in human DCs of lymph nodes from dermatopathic lymphadenopathy patients. Interestingly, Nrp1-expressing DCs were concentrated in the T-cell-rich areas, suggesting that Nrp1 pathway can influence DC-T-cell interaction and supporting previous findings in which Nrp1 is involved in the formation of the immunologic synapse. Nrp1 is also expressed on peripheral blood T cells. Together, these observations suggest that Nrp1 plays a role in promoting cognate interactions between DC and T cells perhaps through the formation of the immunological synapse necessary to initiate the immune response. Evidence to support this hypothesis is provided from *in vitro* studies using allogeneic DC-T-cell co-cultures that demonstrated Nrp1 expression to be co-localized with CD3 expression on T cells and required for T-cell proliferation; Nrp1 blocking antibodies diminished the ∼50--60% T-cell proliferation when antibodies were directed to Nrp1 on DC or T-cell ([@B20]).

Corbel et al. characterized Nrp1 expression on murine thymocytes and other cell populations ([@B21]). First, they analyzed Nrp1 expression on both immature and mature bone marrow-derived DCs (BM-DCs) and found that ∼5% of immature BM-DCs express Nrp1 in the cell surface. This frequency increases to ∼45% of LPS-matured BM-DCs. In the thymus, ∼40--50% of leukocytes express Nrp1 (mainly by DN, DP, and CD4+CD25+ T cells) ([@B21]). In a very interesting report, it is proposed that Nrp1 expressed on human DCs can be transferred onto T cells via trogocytosis since Nrp1 expression on CD4+ T cells occurs as early as 15 min post co-culture with DCs. This was confirmed using an inhibitor for protein synthesis (in which case Nrp1 detection on T cells still occurred) and performing co-cultures with B cells (as antigen presenting cells) transduced with a vector containing a reporter (GFP) Nrp1. In these experiments, CD4+ T cells cultured with Nrp1^GFP^-B cells express Nrp1^GFP^ in the membrane, and the level of expression is directly correlated with the amount of expression on B cells. Cell-contact and membrane transfer were confirmed using transwell experiments and membrane dye assays, respectively. Their results propose an interesting mechanism by which CD4+ T cells may be acquiring Nrp1 from DCs to modulate the immune response (by binding to Nrp1 ligands or interacting with other cells), but since there was not activation of CD4+ T-cell signaling pathways upon Nrp1 binding, the mechanism and relevant *in vivo* impact of this phenomenon are still unknown ([@B21]).

### Regulatory T cells {#S1-3-7}

Two years after Tordjman's findings, Bruder et al. studied the expression of Nrp1 on murine CD4+ T cells ([@B22]). In this work, they isolated CD4+CD25+ regulatory T cells (Tregs) and CD4+CD25− T cells (activated or not *in vitro*) and performed gene array analysis. In these experiments, Tregs could be distinguished from the CD4+CD25− T-cell counterparts by a defined group of differentially expressed genes, which contained Foxp3, KLRG1, and Nrp1. Nrp1 expression on Tregs at the plasma membrane was confirmed using antibody surface staining. Polyclonal and antigen-specific activation of Tregs *in vitro* demonstrated that the level of Nrp1 remains unchanged on Tregs, while Nrp1 expression on activated CD4+ T cells is almost lost ([@B22]). Bruder et al. also demonstrated that Nrp1 expression is directly related with both, Foxp3 expression and suppressive properties on Tregs.

Sarris et al. analyzed the contribution of Nrp1 expression on Tregs and its role in the formation of immune synapse with DCs, antigen recognition, and proliferation ([@B23]). In this report, the authors used time-lapsed video microscopy to quantify the duration of Tregs and DCs interaction. Results from these studies indicated that naïve CD4+ T cells and Tregs establish long-lasting interactions (\>400 s) with DCs in a MHC-II-dependent manner, but the frequency of cells interacting with DCs was twofold higher with Tregs (∼44%) compared to naïve CD4+ T cells (∼23%). Most importantly, the long-lasting interactions between DCs and Tregs were dependent on Nrp1 since the incubation of either DCs or Tregs with a Nrp1 blocking antibody reduced their interactions. This finding suggests that homotypic expression of Nrp1 by DCs and Tregs may contribute to this process. Further analyses demonstrated that Nrp1 plays a role in immune synapse formation (being present in pSMAC and cSMAC) as well as in antigen recognition and T-cell proliferation, since Nrp1 expression would make T cells more sensitive to antigen ([@B23]). Although the data described above suggests that Nrp1 is preferentially expressed by Tregs, Milpied et al. reported that human PBMC CD4+CD25+Foxp3+ T cells express extremely low levels of Nrp1, concluding that Nrp1 cannot be used to distinguish human Tregs from conventional CD4+ T cells ([@B82]).

Besides the chemoattractant property between DC-T cells and its role in the formation of the immunological synapse, Glinka and Prud'homme proposed a role for Nrp1 as a transforming growth factor-β (TGF-β) receptor ([@B83]). They designed an Nrp1-Fc molecule, which when added to T cells in culture could bind to LAP-TGFβ or active TGFβ. Importantly, CD4+Nrp1− T cells bind to LAP-TGFβ via Nrp1-Fc gaining suppressive capacity.

The *in vivo* importance of Nrp1 expression on CD4+ T cells was determined by Solomon et al. through analysis of Nrp-1^flox/flox^CD4^Cre^ conditional knockout mice where both CD4+ and CD8+ T cells lack Nrp1 ([@B84]). These mice have normal T-cell development, including normal levels of Foxp3 expression in CD4+CD25+ T cells compared with control littermates. Nrp-1^flox/flox^CD4^Cre^ mice developed a more severe EAE characterized by CD4+ T cells skewed toward a Th17 phenotype, given by an up-regulation in the expression of RORγτ and enhanced IL-17 secretion. CD4+CD25+ T cells from the Nrp-1^flox/flox^CD4^Cre^ mice display a lack of their suppressive function despite normal Foxp3 expression levels. The suppression displayed by CD4+Nrp1+ T cells seems to be dependent on TGF-β since the inclusion of a TGF-β blocking antibody into DC-CD4+ T-cell co-cultures, in the presence of CD4+Nrp1+ T cells, abrogates suppression ([@B84]). This result was not obtained when an IL-10 blocking antibody was evaluated.

In 2012, two independent research groups reported that Nrp1 could be a useful surface marker to differentiate between natural-Tregs (nTregs) and induced-Tregs (iTregs) ([@B85], [@B86]). Using several transgenic mouse strains, Yadav et al. demonstrated that iTregs express very low levels of Nrp1. Yadav's group has developed an *in vivo* model (based on EAE) in which the offspring of myelin-binding protein (MBP)-TCR-Tg mice crossed with RAG-KO mice lack nTregs, but iTregs can be detected in the periphery. In addition to this, they also tested the low dose-antigen immunization model to induce iTregs. In their experiments, they could identify and isolate iTregs to compare differentially expressed genes by gene arrays analysis, with the nTregs counterpart as control. Results from these experiments demonstrated that Nrp1 is preferentially expressed by nTregs. Nrp1− T cells express Foxp3 and have suppressive function *in vitro* and *in vivo* ([@B85]).

Exploiting *in vivo* models of iTreg generation in mucosa (lung and intestine), Weiss et al. observed the same phenomena but additionally, they tested for possible factors controlling Nrp1 expression. In this attempt, the group identified TGF-β and IL-6 to induce and inhibit Nrp1 expression, respectively ([@B86]).

Conversely, Hansen et al. utilized an *in vivo* tumor model to show that the lack of Nrp1 on CD4+ T cells does not allow tumor growth, mainly by eliciting the effector function of intra-tumoral CD8+ T cells ([@B87]). The depletion of Foxp3+ T cells and disruption of VEGF production on tumor cells mimic the phenotype seen in CD4+ T-cell specific Nrp1-deficient mice. Taken together, these data indicate that tumor-derived VEGF is required to attract CD4+Foxp3+Nrp1+ T cells that can support tumor growth. In the same line, Delgoffe et al. utilized mice with a Foxp3-specific Nrp1 deletion, and found that Nrp1 potentiates Treg cell function and stability both *in vitro* and *in vivo* via interaction with Sema4A expressed in pDCs ([@B67]). The Nrp1-Sema4A binding would allow the interaction between Nrp1 and the cytoplasmic domain of PTEN, inhibiting Akt-mTOR signaling, and favoring Foxo3a nuclear localization, which promotes Foxp3-dependent Treg survival, stability, and function.

Implications in clinical transplantation tolerance {#S1-4}
--------------------------------------------------

Currently in the clinical transplantation field, a molecular marker to identify and track Tregs is lacking because Foxp3 (the hallmark for Tregs) is an intracellular protein, thus it is not a useful tool to identify and isolate viable Tregs. Furthermore, Foxp3 expression in human Tregs is not characteristic of these suppressor cells compared to murine Tregs ([@B82]). Yadav and Weiss's recent reports propose Nrp1 as an attractive new surface marker to distinguish murine Tregs from effector CD4+ T cells, even more, to discriminate between those generated in the periphery (iTregs) from the ones differentiated in the thymus or nTregs ([@B85], [@B86]).

In murine studies, the contribution of Nrp1 biology in transplantation tolerance indicates that CD4+Nrp1+ T cells may play a suppressive role in allograft rejection. One important report shows that CD4+Nrp1+ T cells transferred into heart allograft-recipient mice extend the survival of the transplant, mainly by inhibiting the production of inflammatory cytokines, such as IFN-γ and IL-17, enriching for Tregs and inducing anergy on effector T cells ([@B88]). The suppressive capabilities of the CD4+Nrp1+ T cells were heightened by the co-administration of the immunosuppressant, rapamycin. Taken together, these results demonstrate the potential use of Nrp1+ T cells to abolish or diminish allograft effector responses, which can be complemented with current drugs to maximize the tolerogenic effect. In line with this report, Schliesser et al. generated CD4+CD25+Foxp3+ Treg cells from total mouse CD4+ T-cell *in vitro* through treatments with anti-CD4, TGF-β, and Retinoic acid (RA) or anti-CD4 plus rapamycin, and showed that the majority of Foxp3-expressing Tregs generated under anti-CD4, TGF-β, and RA condition express Nrp1, mainly due to the expansion of nTregs instead of *de novo* iTregs ([@B89]). They also showed that anti-CD4, TGF-β, and RA expanded Tregs exhibited the highest stability and suppressive capacities both *in vitro* and in a skin transplantation setting, highlighting the role of Nrp1 in Treg cells.

In humans, Nrp1 may be a useful indicator of the immunological status of patients. For example, Battaglia et al. analyzed the frequencies of CD4+Nrp1+ T cells in peripheral blood and lymph nodes of patients with benign diseases undergoing lymphadenectomy. Their results show that Foxp3 expression is detected in the CD25high fraction of CD4+Nrp1+ T cells from lymph nodes and not from blood, suggesting an anatomical influence in the presence of Nrp1-expressing CD4+ T cells ([@B90]). Importantly, CD4+Nrp1+CD25high T cells from lymph nodes co-expressed other Treg-like markers such as CD45RO and GITR, and displayed suppressive capability *in vitro*. Interestingly, the frequencies of CD4+Nrp1+CD25high T cells were reduced in the tumor-draining lymph nodes of cervical cancer patients after chemoradiation therapy, which was associated with a decrease in the tumor mass. Based on this data, one possibility is that the presence of human CD4+Nrp1+CD25high T in lymph nodes cooperates with the tolerogenic microenvironment of tumor burden areas ([@B90]).

Finally, a small study proposed the expression of Nrp1 on T cells as a putative predictor of allograft rejection, since the presence of Nrp1 on lymphocytes residing in kidney transplant biopsies decreased during acute rejection, as compared with biopsies from non-rejecting individuals ([@B91]), suggesting that the reduction of Tregs (Nrp1+ cells) in the graft may be linked with the development of the rejection process (see Figure [3](#F3){ref-type="fig"} for an overview of Nrp1 expression on suppressive and effectors CD4+ T cells). This supports the possible use of Nrp1 as a Tregs marker in transplanted patients.

![**Neuropilin-1 expression in DCs and CD4+ T cells**. DC precursors express very low levels of Nrp1. In contrast, mature DCs express high levels of Nrp1. Naïve CD4+CD25− T cells constitutively express Nrp1, which is downregulated upon T-cell activation. Interestingly, nTregs also constitutively express high levels of Nrp1 in contrast to iTregs, distinguishing these two cell populations when combined with Foxp3 expression. The presence of Nrp1+ T cells is associated with acceptance of tissue grafts while Nrp1− T cells are linked to tissue graft rejection.](fimmu-04-00405-g003){#F3}

Conclusion {#S2}
==========

Important advances have been made in the study of Nrp1 on immune cells. While most of the available information indicates a role for Nrp1 in the formation of the immunological synapse, Nrp1 may also play a key role as a Treg marker, permitting the discrimination between nTregs and periphery-induced-Tregs. More investigation is required to clearly demonstrate that Nrp1 will be a feasible predictor of tolerance in the transplantation field since murine and human data are not compatible. Hence, the question of whether Nrp1 is a new marker for transplantation tolerance remains to be answered.
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